Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 16, 2008	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs Trans History: 628	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	73,009	$7.41	636,103
Dec 03, 2009	YANCOPOULOS GEORGE Director, EVP CSO & Pres Regn Res Labs Trans History: 628	Director, EVP CSO & Pres Regn Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	45,463	$19.29	642,772
Oct 30, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	3,806	$559.08	679,012
Dec 13, 2017	YANCOPOULOS GEORGE Director, President & CSO Trans History: 628	Director, President & CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	95,050	$385.08	680,612
Oct 30, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	182,818	$11.64	682,818
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	10,429	$380.09	686,571
Dec 03, 2009	YANCOPOULOS GEORGE Director, EVP CSO & Pres Regn Res Labs Trans History: 628	Director, EVP CSO & Pres Regn Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	100,000	$8.77	688,235
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	195,079	$20.32	697,000
Mar 09, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific Trans History: 628	Director, President and Chief Scientific	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	150,000	$30.63	713,990
May 11, 2020	SCHLEIFER LEONARD S Director, President & CEO Trans History: 404	Director, President & CEO	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	187,500	$30.63	722,368

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media